There are a small number of discoveries and inventions that have potential to impact the course of humanity. Tackling age-related disease is one of these. Vincere’s team brings decades of experience in biology, technology, and drug discovery to this fight - so we may all benefit from a brighter tomorrow.- Spring Behrouz
Chief Executive Officer
Pipeline
Vincere develops small molecule therapeutics to improve mitochondrial quality. Natural mechanisms of mitochondrial quality control decline with age, leading to the neurodegeneration seen in Parkinson's disease which affects 10 million patients worldwide.
Partners
Vincere is a recipient of a $1M grant from the Michael J Fox Foundation, a Phase I SBIR grant from the National Institutes of Health (NIH), and is a resident of the JLABS incubator at LabCentral in Cambridge, MA.
Technology
Biology is complex with a rapidly growing body of knowledge. Proprietary simulation and AI from NeuroInitiative enables our team to move faster and synthesize new discoveries into efficient therapeutic programs.
